The Skeletal L-type Ca²⁺ Current Is a Major Contributor to Excitation-coupled Ca²⁺ entry

Roger A. Bannister, 1 Isaac N. Pessah, 2 and Kurt G. Beam 1

¹Department of Physiology and Biophysics, School of Medicine, University of Colorado Denver, Aurora, CO 80045 ²Department of Molecular Biosciences and Center for Children's Environmental Health and Disease Prevention, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616

The term excitation-coupled Ca²⁺ entry (ECCE) designates the entry of extracellular Ca²⁺ into skeletal muscle cells, which occurs in response to prolonged depolarization or pulse trains and depends on the presence of both the 1,4-dihydropyridine receptor (DHPR) in the plasma membrane and the type I ryanodine receptor in the sarcoplasmic reticulum (SR) membrane. The ECCE pathway is blocked by pharmacological agents that also block store-operated Ca²⁺ entry, is inhibited by dantrolene, is relatively insensitive to the DHP antagonist nifedipine (1 μM), and is permeable to Mn²⁺. Here, we have examined the effects of these agents on the L-type Ca²⁺ current conducted via the DHPR. We found that the nonspecific cation channel antagonists (2-APB, SKF 96356, La³⁺, and Gd³⁺) and dantrolene all inhibited the L-type Ca²⁺ current. In addition, complete (>97%) block of the L-type current required concentrations of nifedipine >10 μM. Like ECCE, the L-type Ca²⁺ channel displays permeability to Mn²⁺ in the absence of external Ca²⁺ and produces a Ca²⁺ current that persists during prolonged (~10-second) depolarization. This current appears to contribute to the Ca²⁺ transient observed during prolonged KCl depolarization of intact myotubes because (1) the transients in normal myotubes decayed more rapidly in the absence of external Ca^{2+} ; (2) the transients in dysgenic myotubes expressing SkEIIIK (a DHPR α_{1S} pore mutant thought to conduct only monovalent cations) had a time course like that of normal myotubes in Ca^{2+} -free solution and were unaffected by Ca²⁺ removal; and (3) after block of SR Ca²⁺ release by 200 µM ryanodine, normal myotubes still displayed a large Ca²⁺ transient, whereas no transient was detectable in SkEIIIK-expressing dysgenic myotubes. Collectively, these results indicate that the skeletal muscle L-type channel is a major contributor to the Ca²⁺ entry attributed to ECCE.

INTRODUCTION

The skeletal muscle L-type Ca2+ channel (1,4-dihydropyridine receptor [DHPR]) serves as the voltage sensor for excitation-contraction (EC) coupling (Tanabe et al., 1988). Conformational changes in the DHPR in response to membrane depolarization are coupled to gating of the type 1 RYR (RYR1) of the SR (Beam and Horowicz, 2004). The resultant Ca²⁺ efflux via RYR1 into the myoplasm initiates contraction (Beam and Horowicz, 2004). It has also been reported that the interaction between the DHPR and RYR1 activates entry of extracellular Ca²⁺ into the myoplasm via an as yet unidentified pathway (Cherednichenko et al., 2004, 2008; Hurne et al., 2005; Yang et al., 2007; Gach et al., 2008; Lyfenko and Dirksen, 2008). This form of Ca²⁺ entry, termed excitation-coupled Ca²⁺ entry (ECCE), requires expression of both the DHPR and RYR1, as ECCE is absent in dysgenic (DHPR α_{1S} subunit–null) and dyspedic (RYR1-null) myotubes, respectively. Cherednichenko et al. (2004) proposed that ECCE is independent of L-type Ca²⁺ current via the DHPR because ECCE (as assessed

by Mn^{2+} quench of the ratiometric Ca^{2+} indicator Fura-2) persists in dysgenic myotubes transfected with an α_{1S} pore mutant (SkEIIIK) thought to conduct only monovalent cations (Dirksen and Beam, 1999). Thus, it was proposed that ECCE involved an as yet unidentified channel activated by conformational coupling to both the DHPR and RYR1.

When myotubes are stimulated either by maintained depolarization with KCl or by repetitive, brief electrical stimuli, myoplasmic Ca²⁺ levels initially rise and then decay as a consequence of declining release from the SR, although this decay is slowed by the entry of external Ca²⁺ associated with ECCE (Yang et al., 2007; Cherednichenko et al., 2008; Gach et al., 2008). Furthermore, ECCE is accentuated in myotubes expressing RYR1 constructs that carry mutations causing malignant hyperthermia in humans (Yang et al., 2007; Cherednichenko et al., 2008). Thus, it appears that ECCE may be important in normal skeletal muscle for helping to maintain force generation during tetanic

Correspondence to Kurt G. Beam: kurt.beam@uchsc.edu

Abbreviations used in this paper: 2-APB, 2-aminoethyl diphenylborate; DHPR, 1,4-dihydropyridine receptor; EC, excitation–contraction; ECCE, excitation-coupled Ca²⁺ entry; SOCE, store-operated Ca²⁺ entry.

^{© 2009} Bannister et al. This article is distributed under the terms of an Attribution–Non-commercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jgp.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

stimulation, and that accentuated ECCE may contribute to the pathophysiological increase in myoplasmic Ca²⁺ that occurs during episodes of malignant hyperthermia.

ECCE is blocked by 2-aminoethyl diphenylborate (2-APB), SKF 96356, La³⁺, and Gd³⁺ (Cherednichenko et al., 2004; Hurne et al., 2005) and thus has a pharmacological profile similar to that of store-operated Ca²⁺ entry (SOCE) and transient receptor potential–like channels. However, ECCE can occur without any store depletion (Cherednichenko et al., 2004, 2008; Hurne et al., 2005; Yang et al., 2007; Gach et al., 2008; Lyfenko and Dirksen, 2008) or in cells in which stores are fully depleted (Cherednichenko et al., 2004; Gach et al., 2008). Furthermore, all attempts to identify transient receptor potential or SOCE channels as the molecular basis of ECCE have failed (Lee et al., 2006; Lyfenko and Dirksen, 2008; Woo et al., 2008).

While attempting to identify the Ca²⁺ current associated with ECCE, we noticed that 2-APB, SKF 96356, La³⁺, and Gd³⁺ each block the skeletal muscle L-type current, as has been reported for ECCE (Cherednichenko et al., 2004; Hurne et al., 2005; Yang et al., 2007). These results prompted us to reexamine the similarities and differences between the skeletal muscle L-type current and ECCE. We found that the L-type current is incompletely (~50%) blocked by 1 μM nifedipine and partially inhibited by the anti-malignant hyperthermia drug dantrolene, as described previously for ECCE (Yang et al., 2007; Cherednichenko et al., 2008). Also like ECCE (Cherednichenko et al., 2004, 2008; Hurne et al., 2005; Gach et al., 2008; Lyfenko and Dirksen, 2008), we found that the L-type channel can conduct Mn²⁺ in the absence of external Ca²⁺.

In addition to examining the pharmacology of the DHPR, we evaluated the contribution of the L-type current to myoplasmic Ca²⁺ transients. In normal myotubes, the Ca²⁺ transient decays during maintained depolarization due to inactivation of EC coupling (Beam and Horowicz, 2004). This decay is accelerated by the removal of external Ca²⁺ or by the addition of Gd³⁺, consistent with the idea that Ca²⁺ entry contributes to the transient (Cherednichenko et al., 2004; Yang et al., 2007). In the present study, a substantial contribution of L-type current to this entry was revealed by the observation that the decay of the myoplamsic Ca²⁺ transient in dysgenic cells expressing SkEIIIK was essentially unchanged by the removal of extracellular Ca²⁺ and resembled that of normal myotubes in the absence of external Ca²⁺ or in the presence of Gd³⁺. Furthermore, when intracellular Ca²⁺ release was blocked by ryanodine, no Ca²⁺ transients were detectable in SkEIIIK-expressing dysgenic myotubes. Collectively, our results indicate that the skeletal muscle L-type Ca2+ current is a major contributor to the Ca²⁺ entry that occurs during depolarization of myotubes.

MATERIALS AND METHODS

Myotube Culture and cDNA Expression

All procedures involving mice were approved by the University of Colorado Denver Institutional Animal Care and Use Committee. Primary cultures of normal (+/+ or +/mdg), dysgenic (mdg/mdg), dyspedic $(RYR1^{-}/RYR1^{-})$, and β_1 -null $(\beta_1^{-}/\beta_1^{-})$ myotubes were prepared as described previously (Beam and Franzini-Armstrong, 1997). Cultures were grown for 6-7 d in a humidified 37°C incubator with 5% CO₂ in Dulbecco's modified Eagle's medium (DMEM; Mediatech), supplemented with 10% fetal bovine serum/10% horse serum (Hyclone Laboratories). This medium was then replaced with differentiation medium (DMEM supplemented with 2% horse serum). In experiments that required exogenous expression of SkEIIIK in dysgenic myotubes, single nuclei were microinjected with a solution of plasmid cDNA encoding SkEIIIK (400 ng/µl) (Dirksen and Beam, 1999) and either pEYFP-C1 or pDsRed2-C1 (10 ng/µl; both from Clontech) 2 d after the switch to differentiation medium. Fluorescent myotubes were used in experiments 2 d after microinjection.

Measurement of L-type Ca²⁺ Currents

Pipettes were fabricated from borosilicate glass and had resistances of $\sim 1.5 \text{ M}\Omega$ when filled with internal solution, which consisted of (in mM): 140 Cs-aspartate, 10 Cs₂-EGTA, 5 MgCl₂, and 10 HEPES, pH 7.4, with CsOH. The standard external solution contained (in mM): 145 TEA-Cl, 10 CaCl₂, 0.003 tetrodotoxin, and 10 HEPES, pH 7.4, with TEA-OH. In some experiments, 2 mM CaCl₂, 10 mM MnCl₂, or 0.5 mM MnCl₂ was substituted for 10 mM CaCl₂. For generation of I-V relationships, linear capacitive and leakage currents were determined by averaging the currents elicited by 11 30-mV hyperpolarizing pulses from the holding potential of -80 mV. Test currents were corrected for linear components of leak and capacitive current by digital scaling and subtraction of this average control current. In all other experiments, -P/4 subtraction was used. Electronic compensation was used to reduce the effective series resistance (usually to $<1~\mathrm{M}\Omega$) and the time constant for charging the linear cell capacitance (usually to <0.5 ms). L-type currents were filtered at 2 kHz and digitized at 5-10 kHz. In most cases, a 1-s prepulse to -20 mV followed by a 50-ms repolarization to -50 mV was administered before the test pulse (prepulse protocol; see Adams et al., 1990) to inactivate T-type Ca2+ channels. Cell capacitance was determined by integration of a transient from -80 to -70 mV using Clampex 8.0 (MDS Analytical Technologies) and was used to normalize current amplitudes (pA/pF). I-V curves were fitted using the following equation:

$$I = G_{\text{max}} * (V - V_{\text{rev}}) / \{1 + \exp[-(V - V_{1/2}) / k_G]\},$$
 (1)

where I is the peak current for the test potential V, V_{rev} is the reversal potential, G_{max} is the maximum Ca^{2+} channel conductance, $V_{1/2}$ is the half-maximal activation potential, and k_G is the slope factor. The deactivation phase of SkEIIIK tail currents was fitted as:

$$I(t) = A \left[\exp(-t/\tau) \right] + C, \tag{2}$$

where I(t) is the current at time t after the repolarization, A is the peak tail current amplitude, τ is the deactivation time constant, and C represents the steady current (see Wilkens et al., 2001). All electrophysiological experiments were performed at room temperature (\sim 25°C).

Ca²⁺ Imaging

Myotubes were washed with Ca²⁺/Mg²⁺-free Ringer's solution (in mM: 146 NaCl, 5 KCl, 10 HEPES, and 11 glucose, pH 7.4, with NaOH) twice and loaded with 5 µM Fluo-3-AM (Invitrogen) dissolved in Rodent Ringer's solution (in mM: 146 NaCl, 5 KCl, 2 CaCl₂, 1 MgCl₂, and 10 HEPES, pH 7.4, with NaOH) for 20 min. Myotubes were then washed three times in Rodent Ringer's solution with gentle agitation. Fluo-3-AM-loaded myotubes bathed in either Rodent Ringer's solution or 0 Ca2+ Rodent Ringer's solution (in mM: 146 NaCl, 5 KCl, 3 MgSO₄, and 10 HEPES, pH 7.4, with NaOH) were then placed on the stage of an LSM META scanning laser confocal microscope (Carl Zeiss, Inc.) and viewed under either 10 or 40× magnification. 10–100 µM N-benzyl-p-toluensulfonamide (Sigma-Aldrich) was continuously present in the bath solution (~25°C) to prevent myotube contractions. Fluo-3 was excited with the 488-nm line of an argon laser (30-milliwatt maximum output, operated at 50% or 6.3A, attenuated to 1-2%). The emitted fluorescence was directed to a photomultiplier equipped with either a 505-nm long-pass filter or a 505-530-nm band-pass filter. Confocal fluorescence intensity data were digitized at 8 bits, with the photomultiplier gain and offset adjusted such that maximum pixel intensities were no more than $\sim 70\%$ saturated and cell-free areas had close to zero intensity. Myoplasmic Ca²⁺ transients were elicited by application of high KCl Ringer's solution (in mM: 71 NaCl, 80 KCl, 2 CaCl₂, 1 MgCl₂, and 10 HEPES, pH 7.4, with NaOH) or 0 Ca²⁺/high KCl Ringer's solution (in mM: 71 NaCl, 80 KCl, 3 MgSO₄, and 10 HEPES, pH 7.4, with NaOH) via an extracellular pipette placed near the myotube of interest or a manually operated, gravity-driven global perfusion system that produced complete exchange within \sim 5 s. Although slower, the latter method had the advantage of producing an exposure to high KCl that was more uniform for entire myotubes and allowed the sampling of responses from many myotubes simultaneously, which was especially useful for myotubes expressing the SkEIIIK construct. Fluorescence amplitude data are expressed as $\Delta F/F$, where F represents the baseline fluorescence before the application of high KCl Ringer's solution, and ΔF represents the change in peak fluorescence during the application of high KCl Ringer's solution. In addition to peak $\Delta F/F$, the following parameters were assessed: (1) t_{peak} = [time at peak ΔF] – [time at onset of the upswing of the transient], (2) $t_{1/2 \text{ decay}}$ = time of decay from peak to 50% of peak $\Delta F/2$, and (3) $r_{20} = [\Delta F]$ at the end of a 20-s KCl depolarization]/[peak Δ F] × 100.

Pharmacology

Ryanodine (Sigma-Aldrich) was reconstituted in 40% EtOH and diluted to 200 µM in differentiation medium. GdCl₃ (Sigma-Aldrich) or LaCl₃ (Sigma-Aldrich) was dissolved in water to make 0.1-M stock solutions and was then added to standard external recording solution for a final trivalent cation concentration of 100 μM. 2-APB (Sigma-Aldrich) and SKF 96356 (provided by O. Delbono, Wake Forest University, Winston-Salem, NC) were dissolved in DMSO (Sigma-Aldrich) to make 1-M and 50-mM stock solutions, respectively. Nifedipine (EMD) was dissolved in 50% EtOH and diluted to various concentrations just before experiments. In some experiments, Ca²⁺ currents were recorded in the continuous presence of 5 µM of racemic Bay K 8644 (provided by A. Scriabine, Miles Laboratories Inc., New Haven, CT) in the bath solution. Racemic Bay K 8644 was stored as a 20-mM stock in 50% EtOH. Dantrolene (Sigma-Aldrich) was dissolved in dry DMSO to make a 20-mM stock solution and diluted to 10 µM just before use. Dihydropyridines, 2-APB, SKF 96356, and dantrolene were stored and used in the dark.


Analysis

Figures were made using the software program SigmaPlot (version 7.0; SSPS Inc.). All data are presented as mean \pm SEM. Statis-

tical comparisons were by ANOVA or by unpaired two-tailed t test (as appropriate), with P < 0.05 considered significant.

Online Supplemental Material

Fig. S1 shows that SKF 96356 accelerated the inactivation kinetics of the L-type current sufficiently so that block was essentially complete at test pulses slightly longer than the test pulse shown in Fig. 1 D. Fig. S2 shows the I-V relationships for dysgenic myotubes expressing SkEIIIK in the presence and absence of 5 μ M \pm Bay K 8644. Fig. S3 shows that the anti-malignant hyperthermia drug dantrolene partially inhibits Ca²⁺ entry during long



cific cation channel antagonists. Acute block of L-type currents evoked by step depolarizations to +30 mV by 100 µM Gd³⁺ (A), $100 \mu M La^{3+}$ (B), $100 \mu M 2$ -APB (C), and $20 \mu M$ SKF 96356 (D). The test pulse was applied after a prepulse protocol (see Materials and methods) (Adams et al., 1990). Results of these experiments and application of DMSO vehicle (0.01%) control experiments are summarized in E. For trivalent cations, maximal block was generally achieved in <30 s after gravity perfusion of the 30-mm dish, whereas longer perfusion times were required for maximal block by 2-APB (1-2 min) and SKF 96356 (2-3 min). The asterisk indicates a significant difference for current (measured at the end of a 200-ms test pulse) remaining in myotubes exposed to blockers relative to DMSO-treated control cells (P < 0.0001, ANOVA). Although not indicated, block by SKF 96356 measured at the end of a 500-ms test pulse was also significantly (P < 0.00008, t test) different than DMSO controls. Throughout, the error bars represent ± SEM.




Figure 2. Block of skeletal L-type current by nifedipine. (A) Incomplete block of L-type current by 1 μM nifedipine. (B) Incomplete block of L-type current by 10 μM nifedipine. (C) Complete block of L-type current by 50 μM nifedipine. Currents evoked by step depolarizations to +30 mV from -50 mV after a prepulse protocol (see Materials and methods). (D) Dose–response relationship for the effects of nifedipine, which were measured $\sim\!\!1$ min after addition. Note that the minimal apparent block (at 1 nM) was $\sim\!\!80\%$, most likely as a consequence of current rundown. Each symbol represents data collected from 2–10 cells.

exposures to elevated KCl. Figs. S1–S3 are available at http://www.jgp.org/cgi/content/full/jgp.200810105/DC1.

RESULTS

L-type Current Is Blocked by Nonspecific Cation Channel Blockers

ECCE can be blocked by exposure to trivalent metal ions (Gd³+ and La³+) and to the nonspecific cation channel blockers 2-APB and SKF 96356 (Cherednichenko et al., 2004; Hurne et al., 2005; Yang et al., 2007). Fig. 1 (A and B) shows that Gd³+ and La³+ (both 100 μM) potently blocked the skeletal L-type current by 96 ± 1% (n = 7) and 97 ± 1% (n = 4), respectively. Substantial block of the L-type current was also produced by exposure of normal myotubes to 100 μM 2-APB (87 ± 2%; n = 6; Fig. 1 C) and to 20 μM SKF 96356 (at the end of 200-ms test pulses: 81 ± 3%; n = 4; Fig. 1 D). Moreover, SKF 96356 accelerated

the inactivation kinetics of the L-type current sufficiently so that block was essentially complete (98 \pm 2% block; n = 3) at 500 ms (Fig. S1). The L-type current was not appreciably affected by exposure to DMSO vehicle (7 \pm 5%; n = 3; P < 0.0001, ANOVA; Fig. 1 E).

Complete Block of Skeletal L-type Current Requires a High Concentration of Nifedipine

A small component of ECCE is blocked by the 1,4-dihydropyridine L-type Ca²⁺ channel antagonist, nifedipine (1 μ M) (Yang et al., 2007), whereas ECCE is completely blocked by 50 μ M nifedipine (see Fig. 7 C). Block of the L-type current showed a similar dependence on nifedipine dose; only partial block was produced by either 1 or 10 μ M nifedipine (Fig. 2, A and B), whereas nearly complete block required 50 μ M nifedipine (Fig. 2 C). The dose–response curve for nifedipine is shown in Fig. 2 D.

TABLE | Conductance Fits

	G-V		
-	G_{max} (nS/nF)	$V_{1/2} \ m (mV)$	$k_G \ m (mV)$
normal (10 mM Ca ²⁺ external)	244 ± 12 (10)	18.1 ± 1.4	4.4 ± 0.2
normal (2 mM Ca ²⁺ external)	115 ± 16^{a} (4)	$7.8 \pm 2.4^{\rm b}$	4.7 ± 0.5
normal (10 mM Ca ²⁺ external) + 10 μM dantrolene	228 ± 10 (12)	$22.4 \pm 0.8^{\rm b}$	$5.2 \pm 0.2^{\rm b}$
normal (10 mM Mn ²⁺ external)	135 ± 6^{b} (4)	16.7 ± 1.9	$5.6 \pm 0.2^{\rm b}$

Data are given as mean \pm SEM, with the numbers in parentheses indicating the number of myotubes tested. Data were fit according to Eq. 1 (see Materials and Methods). Asterisks indicate significant differences compared to L-type currents recorded from normal, untreated myotubes in 10 mM external Ca²⁺ 4 P < 10^{-4} , t test.

 $^{{}^{}b}P < 0.01$, t test.

Dantrolene Inhibits L-type Currents

The anti-malignant hyperthermia drug dantrolene at $10~\mu\mathrm{M}$ blocks $\sim\!65\%$ of ECCE as measured by $\mathrm{Mn^{2+}}$ quench (Cherednichenko et al., 2008). We found that $10~\mu\mathrm{M}$ dantrolene also inhibited the L-type current in myotubes (Fig. 3 and Table I). At $+30~\mathrm{mV}$ (near the peak of the I-V relationship), dantrolene inhibited L-type current by $\sim\!19\%$ compared with untreated control myotubes ($-9.7 \pm 0.6~\mathrm{pA/pF}$; $n=12~\mathrm{vs.}-11.9 \pm 0.5~\mathrm{pA/pF}$; n=10, respectively; P<0.05). Dantrolene also caused an $\sim\!5$ -mV depolarizing shift in the I-V relationship (Fig. 3 C). Collectively, the data presented in Figs. 1–3 indicate that the skeletal L-type Ca²⁺ current and ECCE have very similar pharmacological profiles.




Figure 3. Dantrolene inhibits skeletal L-type Ca^{2+} currents. Recordings of L-type currents elicited by 200-ms depolarizations from -50 mV to the indicated test potentials are shown for an untreated normal myotube (A) or a normal myotube exposed to $10 \mu M$ dantrolene for >10 min at ~ 25 °C (B). (C) Comparison of I-V relationships for untreated (\bullet ; n=10) and dantrolene-treated myotubes (\bigcirc ; n=12). Currents were evoked at 0.1 Hz in 10-mV increments after a prepulse protocol (see Materials and methods). Current amplitudes were normalized by linear cell capacitance (pA/pF). The smooth curves are plotted according to Eq. 1, with best-fit parameters presented in Table I.

L-type Channels Inactivate Slowly and Conduct Substantial Current at Weak Test Potentials in Physiological Ca²⁺

The pharmacological data described above were obtained using 200-ms test pulses and 10 mM Ca²⁺ in the external recording solution to allow comparison with previous data from our laboratory. Under these conditions, no L-type current was observable at test potentials below +10 mV. In contrast, ECCE can be strongly evoked by \sim 80 mM KCl (Hurne et al., 2005), which results in depolarizations to between -10 and 0 mV (Allen, P.D., and J.R. López, personal communication). To determine whether L-type current can be observed in the same range of potentials as ECCE, we reduced the external Ca²⁺ to the more physiological 2 mM used for the ECCE measurements (Cherednichenko et al., 2004, 2008; Hurne et al., 2005; Yang et al., 2007; Gach et al., 2008; Lyfenko and Dirksen, 2008). This maneuver reduced L-type current amplitude and caused an ~11-mV hyperpolarizing shift in the peak I-V relationship measured with 200-ms test pulses (P = 0.0011; Fig. 4 A and Table I). However, the currents were much larger with \sim 10-s depolarizations




Figure 4. In 2 mM of external Ca²+, L-type currents are activated by weak depolarizations and inactivate very slowly. (A) Comparison of I-V relationships for normal myotubes in 10 mM of external Ca²+ (●; n=10) or 2 mM of external Ca²+ (○; n=4) elicited at 0.1 Hz by test potentials ranging from −20 through +80 mV in 10-mV increments after a prepulse protocol. The smooth curves are plotted according to Eq. 1. The best-fit parameters for each plot are presented in Table I. (B) Recordings of L-type currents in 2 mM of external Ca²+ elicited by 9,800-ms depolarizations from −80 mV to the indicated test potentials.

TABLE II

Activation and Decay of L-type Current during Extended Depolarizations

	${\rm I_{peak} \atop (pA/pF)}$	$t_{ m peak} \ ({ m s})$	$t_{1/2 m decay} \ (s)$	r ₉ (%)
normal (-10 mV)	-0.7 ± 0.2 (5)	4.02 ± 1.02 (6)	ND	0.64 ± 0.10 (6)
normal (0 mV)	-2.3 ± 0.6 (5)	2.54 ± 1.14 (6)	2.65 ± 0.34 (6)	0.52 ± 0.10 (6)

Data presented here were obtained from 9.8-s test potentials from -80 to -10 and 0 mV with 2 mM Ca^{2+} in the external recording solution. r_9 is ratio of the current remaining at 9 s to the peak current. $t_{1/2\ decay}$ at $-10\ mV$ was not determined (ND) because the test potential was too short to accurately assess this parameter in three of six cells. Data are given as mean \pm SEM, with the numbers in parentheses indicating the number of myotubes tested.

like those used to elicit ECCE (Cherednichenko et al., 2004; Hurne et al., 2005) because activation was so slow (Fig. 4 B). In particular, L-type currents evoked at $-10 \,\mathrm{mV}$ in 2 mM Ca²⁺ had a time-to-peak of $4.02 \pm 1.02 \,\mathrm{s}$ (n = 6; Table II). Furthermore, the current inactivated very little under these conditions (36% in 9 s; Table II). Collectively, the data in Fig. 4 indicate that long, weak depolarizations elicit substantial, sustained L-type current in the presence of physiological Ca²⁺.

Skeletal Muscle L-type Channels Pass Mn²⁺

In addition to producing Ca^{2+} entry measurable as a component of myoplasmic Ca^{2+} transients (compare with Yang et al., 2007), ECCE can be assayed by quench of Fura-2 fluorescence resulting from Mn^{2+} influx in the absence of extracellular Ca^{2+} (Cherednichenko et al., 2004, 2008; Hurne et al., 2005; Gach et al., 2008; Lyfenko and Dirksen, 2008). Fig. 5 A shows that the L-type channel also conducts Mn^{2+} ions in the absence of external Ca^{2+} (peak current of -4.1 ± 0.3 pA/pF at +30 mV; n=4). Under standard recording conditions (10 mM

external Ca²⁺), large L-type Ca²⁺ currents were observed at depolarizations to +30 mV (Fig. 5 B, bottom trace). A substantial current remained upon the replacement of 10 mM Ca²⁺ by 10 mM Mn²⁺ (Fig. 5 B, middle trace). This Mn²⁺ current was blocked nearly completely by 10 μ M nifedipine (95 ± 2% channel block; n = 4), confirming that the Mn²⁺ entry was indeed via L-type channels (Fig. 5 B, top trace).

To approximate the conditions that have been previously used to measure ECCE via $\mathrm{Mn^{2+}}$ quench, we also recorded L-type currents in the presence of 0.5 mM $\mathrm{Mn^{2+}}$ (Fig. 5 C). Under these conditions, the average current amplitude was reduced (Fig. 5 D), and there was a substantial hyperpolarizing shift in the activation of the $\mathrm{Mn^{2+}}$ current (i.e., peaking at \sim 0 mV; Fig. 5, C and D).

Ca²⁺ Influx via the L-type Channel Accounts for the Majority of Ca²⁺ Influx in Response to Extended Depolarization

Cherednichenko et al. (2004) found that ECCE could be detected in dysgenic myotubes after the expression





Figure 5. The skeletal muscle L-type channel conducts Mn2+. (A) I-V relationship for normal myotubes in 10 mM of external Mn^{2+} (\bigcirc ; n = 4) for currents elicited at 0.1 Hz by test potentials ranging from -20 through +80 mV in 10-mV increments after a prepulse protocol. The smooth curves are plotted according to Eq. 1. The best-fit parameters for each plot are presented in Table I. (B) Representative currents recorded at +30 mV from a normal myotube in 10 mM Ca²⁺ (bottom trace), in 10 mM Mn²⁺ (middle trace), and in 10 mM $Mn^{2\text{+}}$ after acute application of 10 μM nifedipine (top trace). (C) L-type current evoked by steps from -50 to 0 mV (top) and to +30mV (bottom) in 0.5 mM Mn²⁺. (D) Average peak currents in 10 mM of divalent cation at a test potential of +30 mV (left) and for 0.5 mM Mn²⁺ at the indicated test potentials (right).

of a DHPR α_{1S} subunit in which a conserved glutamate in the pore-forming region of repeat III was mutated to lysine (SkEIIIK) (Dirksen and Beam, 1999). Because SkEIIIK produces no obvious inward Ca²⁺ current during 200-ms depolarizations or subsequent repolarization (Dirksen and Beam, 1999) (Fig. S2), it was concluded that ECCE was independent of cation flux via the L-type channel. To assess a potential contribution of the L-type current to ECCE, we compared myoplasmic Ca²⁺ transients that were elicited locally by 20-s exposures to elevated (80 mM) KCl in both untransfected normal myotubes and dysgenic myotubes expressing SkEIIIK. Ca²⁺ transients of normal myotubes elicited by locally applied 80 mM KCl (Fig. 6 A) rose to a peak and decayed slowly (t_{1/2 decay} = 10.64 ± 0.98 s; n =24) and incompletely ($r_{20} = 31.92 \pm 5.03\%$). As shown in Fig. 6 B, transients of normal myotubes obtained in nominally 0 mM Ca^{2+} decayed much faster ($t_{1/2 \text{ decay}} =$ 4.98 ± 0.45 s; n = 12; P < 0.0005, t test) and more completely ($r_{20} = 4.36 \pm 2.38\%$; P < 0.001, t test) than transients measured in 2 mM Ca²⁺ (Fig. 6, B–D, superimposed gray trace). An accelerated rate of decay was also observed in experiments in which 100 μM Gd³⁺ was added to the 80 KCl Ringer's solution in the micropipette ($t_{1/2 \text{ decay}} = 3.49 \pm 0.47 \text{ s}; r_{20} = 2.23 \pm 0.74\%; n = 14;$ Table III), supporting the idea that the acceleration of decay in 0 mM Ca²⁺ resulted from a loss of Ca²⁺ entry rather than from some other effect of removing Ca²⁺ from the bath.



In 2 mM Ca²⁺, high KCl-evoked Ca²⁺ transients of dysgenic myotubes expressing SkEIIIK also decayed more rapidly than Ca²⁺ transients of normal myotubes (Fig. 6 C), having decay kinetics ($t_{1/2 \text{ decay}} = 4.47 \pm 0.52 \text{ s}; r_{20} = 10.41 \pm$ 2.70 s; n = 9; Fig. 6, E and F) more similar to those of normal myotubes in nominally 0 mM Ca²⁺ than in 2 mM Ca²⁺ (Table III). Furthermore, the decay kinetics of Ca²⁺ transients in myotubes expressing SkEIIIK were little affected by the removal of extracellular Ca^{2+} ($t_{1/2 \text{ decay}} =$ 5.68 ± 1.16 s; $r_{20} = 4.97 \pm 2.17\%$; n = 5; Fig. 6, D-F, and Table III). The fact that Ca²⁺ removal accelerated the decay of Ca2+ transients in normal myotubes but not in dysgenic myotubes expressing SkEIIIK is consistent with the idea that Ca2+ entry slows the decay of transients in normal myotubes bathed in 2 mM Ca²⁺, and that this entry does not occur for SkEIIIK.

In control experiments, untransfected dysgenic and dyspedic myotubes failed to respond to locally applied 80 mM KCl (n = 12 and 14, respectively; Table III). Myotubes harvested from mice null for the DHPR β_1 subunit also failed to respond to locally applied 80 mM KCl Ringer's solution (n = 10; Table III).

SkEIIIK Supports Minimal Ca²⁺ Entry during Long, Global Depolarizations

To assess changes in myoplasmic Ca^{2+} attributable solely to Ca^{2+} influx, we applied 80 mM KCl globally to myotubes after block of intracellular Ca^{2+} release by ryanodine pretreatment (200 μ M; > 1 h; 37°C). Under these

Figure 6. Ca²⁺ influx via the L-type channel accounts for the bulk of Ca²⁺ influx in response to depolarization. Representative Ca²⁺ transients are shown for a normal myotube in 2 mM of bath Ca2+ (A), a normal myotube in nominal 0 mM of bath Ca²⁺ (B), a dysgenic myotube expressing SkEIIIK in 2 mM Ca2+ (C), and a dysgenic myotube expressing SkEIIIK in 0 mM Ca²⁺ (D). Summary of t_{1/2 decay} (E) and r₂₀ (F) values for normal myotubes and dysgenic myotubes expressing SkEIIIK in the presence (solid bars) and absence (hatched bars) of 2 mM Ca²⁺. In B-D, a scaled version of the transient shown in A has been included for comparison of the rates of transient decay (gray traces). Transients were elicited locally by 20-s applications of 80 mM KCl via micropipette placed close to the myotube of interest. See Materials and methods for definitions of $t_{1/2 \text{ decay}}$ and r_{20} . Asterisks indicate a significant difference (P < 0.0005, ANOVA).

TABLE III

Activation and Decay of Ca²⁺ Transients during Local Depolarizations

	$\Delta F/F \ (\Delta F/F)$	$egin{array}{c} t_{ m peak} \ (s) \end{array}$	$t_{1/2 \mathrm{decay}} \ (\mathrm{s})$	r ₂₀ (%)
normal (2 mM Ca ²⁺)	3.25 ± 0.35 (24)	3.76 ± 0.34	10.64 ± 0.98	31.92 ± 5.03
normal (0 mM Ca ²⁺)	1.31 ± 0.15^{a} (12)	$1.97 \pm 0.22^{\rm b}$	4.98 ± 0.45^{a}	4.36 ± 2.38^{a}
$normal + 100~\mu M~Gd^{3+}(2~mM~Ca^{2+})$	1.77 ± 0.18^{b} (14)	1.94 ± 0.13^{a}	3.49 ± 0.47^{a}	2.23 ± 0.74^{a}
dysgenic + SkEIIIK (2 mM Ca ²⁺)	0.90 ± 0.18^{a} (9)	3.51 ± 0.50	4.47 ± 0.52^{a}	$10.41 \pm 2.70^{\circ}$
dysgenic + SkEIIIK (0 mM Ca ²⁺)	0.25 ± 0.09^{a} (5)	2.70 ± 0.45	5.68 ± 1.12^{c}	4.97 ± 2.17^{c}
dysgenic (2 mM Ca ²⁺)		no resp	onse (12)	
dyspedic (2 mM Ca ²⁺)		no resp	onse (14)	
β_1 null (2 mM Ca ²⁺)		no resp	onse (10)	
dysgenic + SkEIIIK + ryanodine (2 mM Ca ²⁺)		no resp	onse (20)	

Data presented here were obtained with depolarizations evoked by 20-s applications of 80 mM KCl Ringer's solution via a micropipette placed near the cell of interest. Where indicated, $100 \mu M \text{ Gd}^{3+}$ was added to the 80 mM KCl Ringer's solution in the micropipette. See Materials and methods for definitions of t_{peak} , $t_{1/2}$ decay, and r_{20} . Data are given as mean \pm SEM, with the numbers in parentheses indicating the number of myotubes tested. Footnotes indicate significant differences compared to normal myotubes in 2 mM Ca^{2+} by unpaired t test:

experimental conditions, 40 of 42 normal myotubes showed a large, slowly activating Ca^{2+} entry from the extracellular space in response to global application of 80 mM KCl ($\Delta F/F = 2.11 \pm 0.16$, n = 40; Fig. 7 A). The presence of either 100 μ M Gd^{3+} or 50 μ M nifedipine, which both block the L-type current (Figs. 1 and 2), completely eliminated this slow Ca^{2+} entry (n = 6 and n = 10, respectively; Fig. 7, B and C). In contrast to the robust Ca^{2+} transients observed in ryanodine-treated normal myotubes, no Ca^{2+} transients were detectable ($\Delta F/F < 0.05$) in ryanodine-treated dysgenic myotubes expressing SkEIIIK (n = 31; Fig. 7 D). Collectively, these results support the idea that L-type Ca^{2+} current is a major contributor to Ca^{2+} entry in response to prolonged, weak depolarization.

The SkEIIIK Pore Mutant Allows Inward Divalent Current Previously, it was reported that in dysgenic myotubes expressing SkEIIIK, entry of divalent cations in response to depolarization could be measured with the indicator Fura-2 (Cherednichenko et al., 2004), whereas we were unable to detect such entry with the indicator Fluo-3 (Figs. 6 and 7). Thus, we sought to determine if SkEIIIK could permit a small influx of divalent cations that might have accounted for the signal measured with Fura-2 by Cherednichenko et al. (2004). In this regard, it is important to note that L-type Ca²⁺ channels display at least two distinct open states of either brief or long duration (i.e., Mode 1 and Mode 2 gating, respectively) (Hess et al., 1984; Pietrobon and Hess, 1990; Dirksen and Beam, 1996). Compared with the short-lived open

state, the long-duration open state is relatively unpopulated during 200-ms depolarizations to potentials below about +50 mV (Dirksen and Beam, 1996). However, entry into the long-duration open state does occur during longer depolarizations (e.g., as during extended exposure to elevated KCl) and is accelerated by stronger depolarizations as well as by exposure to dihydropyridine agonists (Hess et al., 1984; Pietrobon and Hess, 1990; Dirksen and Beam, 1996). Importantly, the long duration open state of the wild-type channel preferentially allows inward divalent current (Leuranguer et al., 2003). Thus, we tested whether strong depolarization in the presence of ±Bay K 8644 would cause SkEIIIK to enter a long-lived open state that would produce inward Ca²⁺ tail current upon repolarization.


Fig. 8 A compares currents for depolarizations to either 0 or +80 mV recorded from a dysgenic myotube expressing SkEIIIK and bathed in 5 μ M \pm Bay K 8644. The depolarization to 0 mV, which is near threshold for activation of ionic current, evoked little outward current and resulted in only a small inward current upon the subsequent repolarization to -50 mV. However, the depolarization to 80 mV evoked a robust, slowly activating outward current (see peak I-V in Fig. S2) and resulted in an appreciable, slowly decaying inward current upon repolarization to -50 mV. As shown in Fig. 8 B, this slowly decaying inward current did not appear to be a consequence of the potentiation by \pm Bay K 8644 of the endogenous L-type current that can be present at low levels in dysgenic myotubes (n=14; $I_{\rm dys}$) (Adams and Beam, 1989).

 $^{^{}a}P < 0.001.$

 $^{^{\}mathrm{b}}\mathrm{P} < 0.005.$

 $^{^{}c}P < 0.05$.

+ 200 μM ryanodine



In dysgenic cells expressing SkEIIIK, the presence of ±Bay K 8644 caused the inward current elicited by repolarization from +80 to -50 mV to be both larger and more slowly decaying than in the absence of the DHP agonist (Fig. 8 C), consistent with the idea that the inward current represents Ca²⁺ influx through channels relaxing from the long open state to closed. The total charge transported during the inward current elicited by repolarization to -50 mV was obtained by integration and is plotted in Fig. 8 D. The total charge for repolarization from 0 to -50 mV (3.6 \pm 0.7 nC/ μ F; n = 9) was similar to that previously measured (see Fig. 4 of Dirksen and Beam, 1999). This charge was likely to have been nonionic and to have arisen from closed-closed gating transitions of the DHPR because a 200-ms depolarization to 0 mV activates little ionic conductance via SkEIIIK (Dirksen and Beam, 1999). Compared with 0 mV, the total charge was substantially larger for repolarization from $+80 \text{ to } -50 \text{ mV} (10.5 \pm 1.1 \text{ nC/}\mu\text{F}; n = 9)$. A fraction of this additional charge movement (~66% of the total 300% increase) was also likely to have been nonionic and to have arisen from gating transitions that would have occurred for repolarization to -50 mV after a 200ms depolarization to +80 mV, but not after a 200-ms depolarization to 0 mV. Possibly, the remaining portion $(\sim 33\%$ of the 300% increase) of additional charge movement was a consequence of inward Ca²⁺ current that resulted from the entry of a small fraction of the SkEIIIK channels into the long-duration open state that supports such current. In the presence of ±Bay K 8644 (Fig. 8 D, gray bars), the total charge after repolarization from +80 to -50 mV was so large $(33.5 \pm 8.0 \text{ nC/}\mu\text{F}; n =$ 10) compared with that after repolarization from 0 to $-50 \text{ mV} (4.4 \pm 1.0 \text{ nC/}\mu\text{F}; n = 10)$ that it clearly indi-

Figure 7. SkEIIIK supports minimal Ca^{2+} entry during long global depolarizations. Representative Ca^{2+} transients evoked by global perfusion of 80 mM KCl Ringer's solution for normal myotubes (A), normal myotubes exposed to $100~\mu M$ Gd³⁺ (B), normal myotubes exposed to $50~\mu M$ nifedipine (C), and dysgenic myotubes expressing SkEIIIK (D). In each case, myotubes were exposed to $200~\mu M$ ryanodine for >1 h at $37^{\circ}C$ before experiments to block the contribution of RYR1 to the Ca^{2+} transient. In experiments with SkEIIIK, a slower sampling rate was used to minimize any bleaching of the Fluo-3 dye. Expression of SkEIIIK was confirmed by electrically evoked (100~V, 5~ms) contractions (17~of~20~myotubes~tested) before ryanodine treatment (see Papadopoulos et al., 2004).

cated the presence of inward Ca²⁺ current via the mutant L-type channel. Thus, these results strongly support the hypothesis that SkEIIIK can enter into a long-duration




Figure 8. Potentiated SkEIIIK conducts inward Ca²⁺ current. Representative currents are shown for a \pm Bay K 8644–treated (5 μ M) dysgenic myotube expressing SkEIIIK (A) and a \pm Bay K 8644–treated, uninjected dysgenic myotube (B). The inset illustrates the tail currents shown in A on an expanded time base. (C) Summary of amplitudes (left) and deactivation time constants (right) of SkEIIIK tail currents recorded in the absence (n=9) and presence (n=10) of \pm Bay K 8644. (D) Total charge moved obtained by integration of tail currents recorded in the absence (n=9) and presence (n=10) of \pm Bay K 8644 from dysgenic myotubes expressing SkEIIIK. Asterisks indicate significant differences between untreated and \pm Bay K 8644–treated cells (*, P < 0.05; **, P < 0.01, t test).

open state that permits inward divalent cation flux. However, the similarity of Ca²⁺ transient decay in SkEIIIK-expressing dysgenic myotubes in 2 mM Ca²⁺ and normal myotubes in 0 mM Ca²⁺ (Fig. 6 and Table III) and the lack of detectable SkEIIIK-mediated transients in the presence of ryanodine (Fig. 7 D) argues that such a mode of Ca²⁺ permeation via SkEIIIK must be quite small compared with Ca²⁺ entry via the native L-type channel.

DISCUSSION

Here, we demonstrate that the skeletal muscle L-type Ca²⁺ current and ECCE share many common attributes (summarized in Table IV). Thus, the skeletal muscle L-type channel is blocked by nonspecific cation channel antagonists (Fig. 1), requires nearly 50 µM nifedpine for complete channel block (Fig. 2), and is inhibited by dantrolene (Fig. 3). We also show that in 2 mM of external Ca²⁺, the L-type Ca²⁺ current, like ECCE, is persistently activated by weak voltage steps (Fig. 4). In addition, we demonstrate that the L-type channel is permeable to

Mn²⁺ in the absence of bath Ca²⁺ (Fig. 5). During prolonged (20-s) KCl depolarization, Ca²⁺ transients in intact, normal myotubes rise to a peak and then decay, and this decay is more rapid after the removal of external Ca2+ or in the presence of Gd3+; the decay of transients in dysgenic myotubes expressing the DHPR α_{1S} subunit pore mutant (SkEIIIK), which has a low permeability to Ca2+, is similar to that of transients in normal myotubes in a Ca2+-free external medium and is little affected by the removal of extracellular Ca²⁺ (Fig. 6 and Table III). Collectively, these results suggest that Ca²⁺ entry via the L-type channel slows the decay of Ca²⁺ transients during prolonged depolarization of normal myotubes. After block of SR Ca²⁺ release by pretreatment with 200 µM ryanodine, depolarization of normal myotubes still resulted in large myoplasmic Ca²⁺ transients, whereas depolarization did not elicit a detectable transient in dysgenic myotubes expressing SkEIIIK (Fig. 7), providing strong support to the idea that the L-type channel is the predominant source of Ca2+ entry. Although SkEIIIK has very low permeability to Ca²⁺, we

TABLE IV

Common attributes of ECCE and the skeletal muscle L-type current

	- $y = 0$	
	ECCE	I_{L}
Is voltage-dependent	yes ^{a,b}	yes ^{c,d,e}
Conducts Ca ²⁺	$\mathrm{yes^{a,b,c,f}}$	yes ^{c,d,e}
Requires α_{1S} subunit	yes ^{a,b,e}	${ m yes^{c,d}}$
Requires β_{1a} subunit	yes ^e	$increased\ expression^{g,h,i,j}$
Reduced by siRNA against $\alpha_2\delta_1$ subunit	yes ^k	faster inactivation ^{k,l}
Requires RYR1	$\mathrm{yes^{a,b,e,f}}$	greatly potentiated ^{m,n}
Blocked by 100 μ M La ³⁺	substantial ^o	complete ^e
Blocked by 100 μM Gd ³⁺	complete ^{a,p,e}	complete ^e
Blocked by 20 μM SKF 96356	$complete^{a,b,o}$	complete ^e
Blocked by 100 μM 2-APB	$\sim\!\!80\%^{ m a,b}$	$\sim\!\!80\%^{ m e}$
Blocked by 1 μM nifedipine	incomplete ^o	incomplete ^e
Blocked by 50 μM nifedipine	complete ^e	complete ^e
Reduced by ≥10 μM dantrolene	partial ^{e,q}	$\mathrm{modest}^{\mathrm{e,r}}$
Conducts Mn ²⁺	$\mathrm{yes^{a,b,f,k,q}}$	yes ^e
Divalent entry via SkEIIIK	yes ^a	yes ^e
Mediated by Orail/STIM1	$\mathrm{no^f}$	$\mathrm{no^{c,d}}$

References:

^aCherednichenko et al., 2004.

bHurne et al., 2005.

^cBeam et al., 1986.

dTanabe et al., 1988.

eThis paper.

Lyfenko and Dirksen, 2008.

gGregg et al., 1995.

hStrube et al., 1996.

ⁱPapadopoulos et al., 2004.

Sheridan et al., 2004.

kGach et al., 2008.

¹Obermair et al., 2005.

^mNakai et al., 1996.

ⁿAvila and Dirksen, 2000.

[°]Yang et al., 2007.

PCherednichenko et al., 2004, no concentration reported.

^qCherednichenko et al., 2008.

^rSzentesi et al., 2001.

did find that after strong depolarization in the presence of ±Bay K 8644, the channel could conduct inward Ca²⁺ tail currents upon repolarization (Fig. 8).

One very clear conclusion from our results is that any of the manipulations that have been used to evaluate the magnitude of ECCE will necessarily produce changes in current via the L-type Ca²⁺ channel (Table IV) and thus the contribution of the L-type current to the myoplasmic Ca²⁺ transient. For example, the addition of Gd³⁺, 20 μM SKF 96356, and 100 μM 2-APB and the removal of external Ca²⁺ block 80–100% of ECCE (Cherednichenko et al., 2004; Hurne et al., 2005), and we find they also block L-type Ca²⁺ current to a similar extent. Conversely, the relative insensitivity of ECCE to 1 µM nifedipine has been taken as an indication that it is independent of L-type current (Yang et al., 2007). In particular, Yang et al. (2007) reported that 1 µM nifedipine causes only a 5% decrease in the decay of the sustained phase of the KClevoked transient for wild-type RYR1 (Fig. 6 B of Yang et al., 2007), whereas 100 µM La³⁺ causes a 14% decrease (Fig. 4 B of Yang et al., 2007). If it is assumed that the altered decay rate for 100 µM La³⁺ reflected a complete block of ECCE, then 1 µM nifedipine caused a 36% block, close to the \sim 50% block of L-type current that we found for 1 µM nifedipine (Fig. 2 D).

We found that maximal L-type Ca²⁺ currents in myotubes were reduced $\sim 15\%$ by 10 μ M dantrolene (Fig. 3), a similar finding to that of Szentesi et al. (2001), who observed that L-type currents are reduced $\sim 25\%$ in adult rodent fibers by 25 µM dantrolene. These electrophysiological results are in good agreement with the observation that Ca²⁺ transients evoked by 40 mM KCl were reduced ~20% in 10 μM of dantrolene-pretreated myotubes compared with matched control myotubes (Fig. S3). However, an earlier report indicated that 10 µM dantrolene caused a more substantial (~65%) reduction in quench of Fura-2 fluorescence by Mn²⁺ entry in response to 40 mM KCl or electrical stimulation (Cherednichenko et al., 2008). In evaluating the difference in dantrolene sensitivity found in the two sets of experiments, it should be noted that the response of the fluorescent indicator (Fluo-3 to Ca²⁺, Fura-2 to Mn²⁺) depends not only on the magnitude of the entry flux, but also on the divalent affinity of the indicator and on the buffering and removal of the divalent cations that have entered the myoplasm. Consequently, the change in fluorescence might well not depend linearly on the entry flux, making it difficult to directly compare these measurements.

The dependence of ECCE on the presence of both the DHPR α_{1s} subunit and RYR1 (Cherednichenko et al., 2004; Hurne et al., 2005; Lyfenko and Dirksen, 2008) is also a feature of the slow L-type Ca²⁺ current, which is totally absent in dysgenic muscle cells lacking α_{1s} (Beam et al., 1986; Tanabe et al., 1988), and greatly reduced in dyspedic muscle cells lacking RYR1 (Nakai et al., 1996; Avila and Dirksen, 2000). This distinguishes ECCE and

the slow L-type current from SOCE, which functions normally in dysgenic and dyspedic myotubes (Cherednichenko et al., 2004; Hurne et al., 2005; but see Lyfenko and Dirksen, 2008). Another parallel between ECCE and the slow L-type Ca²⁺ current is that myotubes null for the DHPR β_{1a} subunit lack ECCE (Table III) and have greatly reduced expression of L-type current (Gregg et al., 1996; Strube et al., 1996; Papadopoulos et al., 2004; Sheridan et al., 2004). Interestingly, knockdown of the DHPR $\alpha_2\delta_1$ subunit in myotubes by siRNA causes a reduction in ECCE (Gach et al., 2008) and an accelerated inactivation of the L-type Ca2+ current measured with 200-ms depolarizations (Obermair et al., 2005; Gach et al., 2008; Obermair et al., 2008). During prolonged depolarizations, the accelerated inactivation might greatly reduce Ca²⁺ entry via the L-type channel.

Previously, Hurne et al. (2005) attempted unsuccessfully to measure a current associated with ECCE by the application of 6-s test pulses to -20 mV. In retrospect, this result is consistent with the hypothesis that the L-type Ca²⁺ current is a major contributor to the ECCE signal because depolarizations to -20 mV would not have activated L-type current in 10 mM of extracellular Ca²⁺ (Fig. 4 A), as used in the measurements of Hurne et al. (2005). In 2 mM Ca2+, however, the leftward shift of activation has the result that long (\sim 10-s) depolarizations to −10 or 0 mV evoke sustained L-type currents (Fig. 4 B) that would support substantial Ca²⁺ entry under the conditions used for measuring ECCE. In addition, relatively weak depolarizations activate currents carried by Mn²⁺ in the absence of external Ca²⁺ (Fig. 5), which means that the L-type channel would produce Mn²⁺ entry under the conditions used to measure Mn²⁺ quench attributed to ECCE (Table IV).

During prolonged depolarization of normal myotubes, the entry of Ca2+ appears to slow the decay of the myoplasmic Ca²⁺ transient inasmuch as removal of external Ca²⁺ causes the decay to become more rapid (Fig. 6). This same manipulation does not greatly affect the time course of transients in dysgenic myotubes expressing SkEIIIK, which decay much like those of normal myotubes in a Ca2+-free medium. In principle, removing extracellular Ca2+ could not only have eliminated Ca²⁺ entry, but also increased inactivation of the voltage sensor for EC coupling (Brum et al., 1988a,b). Indeed, the amplitude of the Ca²⁺ transients in Ca²⁺-free medium was smaller for both normal myotubes and dysgenic myotubes expressing SkEIIIK (Table III), consistent with the possibility that removal of Ca²⁺ increased steady-state inactivation of voltage sensors in resting myotubes. Cherednichenko et al. (2004) also observed a similar reduction of the KCl-evoked Ca²⁺ transient in a Ca²⁺-free medium. However, altered inactivation during the KCl application does not seem to have been a major factor in causing more rapid decay because: (1) an acceleration of decay like that seen with Ca²⁺ removal was caused by the administration of Gd³⁺ concurrently with the high KCl, and (2) removal of external Ca²⁺ had little effect on the time course of Ca²⁺ transients for SkEIIIK.

Our measurements of Ca2+ transients in intact myotubes strongly support the idea that the L channel is a major contributor to ECCE. These transients were characterized both in myotubes where intracellular release occurred via RYR1 (Fig. 6) and in myotubes in which this release had been blocked by prior exposure to ryanodine (Fig. 7). Under the latter situation, depolarization of normal myotubes, but not dysgenic myotubes expressing SkEIIIK, elicits large Ca²⁺ entry transients. Thus, any Ca²⁺ entry via a pathway other than the L-type channel must be too small to be detected by our experiments (myotubes loaded with Fluo-3-AM). This result raises the obvious question of why previous work found expression of SkEIIIK in dysgenic myotubes restored ECCE as indicated by the entry of either Mn²⁺ or Ca²⁺ (Cherednichenko et al., 2004; their Fig. 4 and not depicted, respectively). One possibility is that SkEIIIK has sufficient permeability to divalent cations to produce a signal detectable by Fura-2 as used by Cherednichenko et al. (2004), but not by Fluo-3 as used in our current experiments. Indeed, our electrophysiological data (Fig. 8) demonstrate that after a brief (200-ms), strong (+80 mV) depolarization in the presence of the DHP agonist ±Bay K 8644, repolarization of cells expressing SkEIIIK results in an inward tail current carried by Ca²⁺ (the only external cation other than TEA). This inward tail current seems likely to be a consequence of the entry of SkEIIIK into a long-duration open state, which has been shown to be promoted in L-type channels by both strong depolarization and DHP agonists (see, for example, Wilkens et al., 2001). Entry into this longduration open state also occurs for much weaker depolarizations in the absence of DHP agonist as long as these depolarizations are sustained (Pietrobon and Hess, 1990). The long-duration open state of both the wildtype cardiac L-type channel and the pore mutant "CEIIIK" appears to be rectifying and to permit the flow of inward divalent current, but not that of outward current (Leuranguer et al., 2003). Thus, it seems a reasonable possibility that SkEIIIK could support a very small inward divalent current during long depolarizations and that this small current might account for the detection of Mn²⁺ entry by means of Fura-2 in myotubes expressing SkEIIIK (Cherednichenko et al., 2004).

In skeletal muscle, the DHPR has dual functions as an L-type Ca²⁺ channel and as the voltage sensor for EC coupling. The physiological role of the L-type Ca²⁺ current has remained obscure because the voltage sensor function of the DHPR does not require the entry of external Ca²⁺ (Fig. 6) (Armstrong et al., 1972; Tanabe et al., 1990; Dirksen and Beam, 1999). However, the results described here support the hypothesis that the L-type Ca²⁺ current mediated by the DHPR is the major (and

perhaps sole) component of ECCE. Previously, the Ca²⁺ entry ascribed to ECCE was shown to help maintain myoplasmic Ca²⁺ levels during either sustained depolarizations or during trains of repetitive brief stimuli (Cherednichenko et al., 2008; Gach et al., 2008). It now appears that this role can be reassigned to the L-type Ca²⁺ current and perhaps represents one of its physiological functions in skeletal muscle.

We are grateful to Dr. O. Delbono (Wake Forest University) for the gift of SKF 96356. We thank Drs. N.M. Lorenzon, A.M. Payne, and D.C. Sheridan, and Mr. J.D. Ohrtman for insightful discussion.

This work was supported in part by grants from the National Institutes of Health (AR44750 to K.G. Beam and AR43140 to I.N. Pessah) and from the Muscular Dystrophy Association (MDA4155 to R.A. Bannister and MDA4319 to K.G. Beam).

Edward N. Pugh Jr. served as editor.

Submitted: 14 August 2008 Accepted: 24 November 2008

REFERENCES

Adams, B.A., and K.G. Beam. 1989. A novel calcium current in dysgenic skeletal muscle. J. Gen. Physiol. 94:429–444.

Adams, B.A., T. Tanabe, A. Mikami, S. Numa, and K.G. Beam. 1990. Intramembrane charge movement restored in dysgenic skeletal muscle by injection of dihydropyridine receptor cDNAs. *Nature*. 346:569–572.

Armstrong, C.M., F.M. Bezanilla, and P. Horowicz. 1972. Twitches in the presence of ethylene glycol bis(-aminoethyl ether)-N,N-tetraacetic acid. *Biochim. Biophys. Acta.* 267:605–608.

Avila, G., and R.T. Dirksen. 2000. Functional impact of the ryanodine receptor on the skeletal muscle L-type Ca²⁺ channel. J. Gen. Physiol. 115:467–480.

Beam, K.G., and C. Franzini-Armstrong. 1997. Functional and structural approaches to the study of excitation-contraction coupling. Methods Cell Biol. 52:283–306.

Beam, K.G., and P. Horowicz. 2004. Excitation-contraction coupling in skeletal muscle. *In Myology*. A.G. Engel and C. Franzini-Armstrong, editors. McGraw-Hill, New York. 257–280.

Beam, K.G., C.M. Knudson, and J.A. Powell. 1986. A lethal mutation in mice eliminates the slow calcium current in skeletal muscle cells. *Nature*. 320:168–170.

Brum, G., R. Fitts, G. Pizarro, and E. Ríos. 1988a. Voltage sensors of the frog skeletal muscle membrane require calcium to function in excitation-contraction coupling. *J. Physiol.* 398:475–505.

Brum, G., E. Ríos, and E. Stefani. 1988b. Effects of extracellular calcium on calcium movements of excitation-contraction coupling in frog skeletal muscle fibers. *J. Physiol.* 398:441–473.

Cherednichenko, G., A.M. Hurne, J.D. Fessenden, E.H. Lee, P.D. Allen, K.G. Beam, and I.N. Pessah. 2004. Conformational activation of Ca²⁺ entry by depolarization of skeletal myotubes. *Proc. Natl. Acad. Sci. USA*. 101:15793–15798.

Cherednichenko, G., C.W. Ward, W. Feng, E. Carabales, L. Michaelson, M. Samsó, J.R. López, P.D. Allen, and I.N. Pessah. 2008. Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. *Mol. Pharmacol.* 73:1203–1212.

Dirksen, R.T., and K.G. Beam. 1996. Unitary behavior of skeletal, cardiac, and chimeric L-type Ca²⁺ channels expressed in dysgenic myotubes. *J. Gen. Physiol.* 107:731–742.

Dirksen, R.T., and K.G. Beam. 1999. Role of calcium permeation in dihydropyridine receptor function. Insights into channel gating and excitation–contraction coupling. J. Gen. Physiol. 114:393–403.

- Gach, M., G. Cherednichenko, C. Haarmann, J.R. Lopez, K.G. Beam, I.N. Pessah, C. Franzini-Armstrong, and P.D. Allen. 2008. Alpha2delta1 dihydropyridine receptor subunit is a critical element for excitation-coupled calcium entry but not for formation of tetrads in skeletal myotubes. *Biophys. J.* 94:3023–3034.
- Gregg, R.G., A. Messing, C. Strube, M. Beurg, R. Moss, M. Behan, M. Sukhareva, S. Haynes, J.A. Powell, R. Coronado, and P.A. Powers. 1996. Absence of the β_{1a} subunit ($\it cchb1$) of the skeletal muscle dihydropyridine receptor alters expression of the α_1 subunit and eliminates excitation-contraction coupling. *Proc. Natl. Acad. Sci. USA*. 93:13961–13966.
- Hess, P., J.B. Lansman, and R.W. Tsien. 1984. Different modes of Ca channel gating behaviour favoured by dihydropyridine agonists and antagonists. *Nature*. 311:538–544.
- Hurne, A.M., J.J. O'Brien, D. Wingrove, G. Cherednichenko, P.D. Allen, K.G. Beam, and I.N. Pessah. 2005. Ryanodine receptor type I (RyR1) mutations C4958S and C4961S reveal excitation-coupled calcium entry (ECCE) is independent of sarcoplasmic reticulum store depletion. J. Biol. Chem. 280:36994–37004.
- Lee, E.H., G. Cherednichenko, I.N. Pessah, and P.D. Allen. 2006. Functional coupling between TRPC3 and RyR1 regulates the expressions of key triadic proteins. *J. Biol. Chem.* 281:10042–10048.
- Leuranguer, V., R.T. Dirksen, and K.G. Beam. 2003. Potentiated L-type Ca²⁺ channels rectify. *J. Gen. Physiol.* 121:541–550.
- Lyfenko, A.D., and R.T. Dirksen. 2008. Differential dependence of store-operated and excitation-coupled Ca²⁺ entry in skeletal muscle on STIM1 and Orai1. *J. Physiol.* 586:4815–4824.
- Nakai, J., R.T. Dirksen, H.T. Nguyen, I.N. Pessah, K.G. Beam, and P.D. Allen. 1996. Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor. *Nature*. 380:72–75.
- Obermair, G.J., G. Kugler, S. Baumgartner, P. Tuluc, M. Grabner, and B.E. Flucher. 2005. The calcium channel $\alpha_2\delta$ -1 subunit determines Ca^{2+} current kinetics in skeletal muscle but not targeting of α_{1S} or excitation-contraction coupling. *J. Biol. Chem.* 280:2229–2237.
- Obermair, G.J., P. Tuluc, and B.E. Flucher. 2008. Auxiliary Ca²⁺ channel subunits: lessons learned from muscle. *Curr. Opin. Pharmacol.* 8:311–318.

- Papadopoulos, S., V. Leuranguer, R.A. Bannister, and K.G. Beam. 2004. Mapping sites of potential proximity between the DHPR and RyR1 in muscle using a CFP-YFP tandem as a FRET probe. *J. Biol. Chem.* 279:44046–44056.
- Pietrobon, D., and P. Hess. 1990. Novel mechanism of voltagedependent gating in L-type calcium channels. *Nature*. 346:651– 655.
- Sheridan, D.C., W. Cheng, L. Carbonneau, C.A. Ahern, and R. Coronado. 2004. Involvement of a heptad repeat in the carboxyl terminus of the dihydropyridine receptor β_{1a} subunit in the mechanism of excitation-contraction coupling in skeletal muscle. Biophys. J. 87:929–942.
- Strube, C., M. Beurg, P.A. Powers, R.G. Gregg, and R. Coronado. 1996. Reduced Ca^{2+} current, charge movement and absence of Ca^{2+} transients in skeletal muscle deficient in dihydorpyridine receptor β_1 subunit. *Biophys. J.* 75:2531–2543.
- Szentesi, P., C. Collet, S. Sárközi, C. Szegedi, I. Jona, V. Jacquemond, L. Kovács, and L. Csernoch. 2001. Effects of dantrolene on steps of excitation-contraction coupling in mammalian skeletal muscle fibers. J. Gen. Physiol. 118:355–375.
- Tanabe, T., K.G. Beam, J.A. Powell, and S. Numa. 1988. Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA. *Nature*. 336:134–139.
- Tanabe, T., K.G. Beam, B.A. Adams, T. Niidome, and S. Numa. 1990.Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. *Nature*. 346:567–569.
- Wilkens, C.M., M. Grabner, and K.G. Beam. 2001. Potentiation of the cardiac L-type Ca^{2+} channel (α_{1C}) by dihydropyridine agonists and strong depolarization occur via distinct mechanisms. *J. Gen. Physiol.* 118:495–508.
- Woo, J.S., D.H. Kim, P.D. Allen, and E.H. Lee. 2008. TRPC3-interacting triadic proteins in skeletal muscle. *Biochem. J.* 411:399–405.
- Yang, T., P.D. Allen, I.N. Pessah, and J.R. López. 2007. Enhanced excitation-coupled calcium entry in myotubes is associated with expression of RyR1 malignant hyperthermia mutations. *J. Biol. Chem.* 282:37471–37478.